Section 1: Project Summary

|  |
| --- |
| **1.1 Title (max 150 characters) [same as Je-S Project Title Non-confidential]** |
|       |

|  |
| --- |
| **1.2 Technical Summary (max 2000 characters) [same as Je-S Technical Summary Non-confidential]** |
|       |

|  |
| --- |
| **1.3 Project Duration and Cost [same as in Je-S submission]**  |
| **RO costs fEC (£)** | 0 |
| **Estimated MRC Contribution @ 80% fEC (£)** | 0 |

Section 2: Investigator Details

See MRC Applicants Handbook for definitions and further information

|  |
| --- |
| **2.1 Principal Investigator [same as Je-S Principal Investigator]** |
| **Name** |       |
| **Post Held** |       |
| **Department** |       |
| **Institution** |       |

|  |
| --- |
| **2.2 Co-Investigators [same as Je-S Co-Investigators]** |
| **Name** | **Organisation** |
|       |       |
|       |       |
|       |       |
|        |       |
|       |       |
|       |       |
|       |       |

Section 3: Host Institute Technology Transfer Office Contact

|  |
| --- |
| **3.1 Host Institute Technology Transfer Office Contact** |
| **Name** |       |
| **Post Held** |       |
| **Department** |       |

Section 4: Need and Approach

|  |
| --- |
| **4.1** **What is the clinical need you are seeking to address? (max 120 words)** |
|       |

|  |
| --- |
| **4.2 What pathway or protein are you proposing to target and what evidence is there linking this to the disease (max 500 words)** |
|       |

|  |
| --- |
| **4.3 What are the competing solutions and their developmental status (all approaches ie not restricted to small molecule approaches)? (max 200 words)** |
|       |

|  |
| --- |
| **4.4 What would be the competitive advantage of your proposed solution and how would it be used clinically? (max 120 words)** |
|       |

|  |
| --- |
| **4.5 Please provide up to 5 relevant references (max 80 words)** |
|       |

|  |
| --- |
| **4.6 Therapeutic Product Profile** |
| **Target name** |       |
| **Target type*****Eg. soluble cytokine,*** ***cell surface protein*** |       |
| **Mechanism of Action** ***Eg. agonist, antagonist*** |       |
| **Proposed therapeutic use*****Eg. disease, subpopulation etc*** |       |
| **Route of administration and dosing frequency*****Eg. IV/sub-cut ; daily/weekly; acute/chronic*** |       |

Section 5: Project Details and Plan

|  |
| --- |
| **5.1 What is the project’s current status? (max 150 words)** |
|       |

|  |
| --- |
| **5.2 Detail the nature and current status of the assay that would be used for primary screening, including details such as is it already compatible to 384 well plates, has it been used before for screening? Does it fulfil the guidelines presented within the applicants guidance? (350 words)**  |
|       |

|  |
| --- |
| **5.3 Detail components that are not commercially available indicating their source/ availability/method of production and any characterisation, degree of purity, etc (300 words max)**  |
|       |

|  |
| --- |
| **5.4 Detail components that are commercially available indicating their source and availability and any relevant details e.g. stability etc (300 words max)**  |
|       |

|  |
| --- |
| **5.6 Detail the assay technology platforms currently used for the primary screen e.g. PE Envision, BMG FSX, LGC IntelliQube, RMD LightCycler, Agilent Rapidfire, Corning Epic, MD FLIPR (100 words max)**  |
|       |

|  |
| --- |
| **5.7 Detail the nature and current status of the assays that will be used for hit confirmation, specificity and or key selectivity (350 words)**  |
|       |

|  |
| --- |
| **5.8 Noting that screening will be performed at the Centre for Lead Discovery, identify and justify any resources requested by the academic research organisation. Indicate if any resources are not readily to hand? (350 words max)** |
|       |

Section 6: Downstream Development

|  |
| --- |
| **6.1 Outline the subsequent application to MRC (or other funders) to develop any hits. Include two-three key progression milestones (one being the project end). For each milestone please set out quantitative success criteria that will be used to ascertain whether the milestone has been met. (max 500 words)** |
|       |

Section 7: Intellectual Property (IP)/Permissions

|  |
| --- |
| **7.1 Does the proposal have freedom to operate or does it require access to background IP? If access is required, what IP does the proposal need access to? (max 120 words)** |
|       |

|  |
| --- |
| **7.2 If access to background IP is required, has access been agreed? If not, why do you believe you will be able to access the required IP on reasonable terms? (max 120 words)** |
|       |

|  |
| --- |
| **7.3 Do you have all the relevant permissions and safety certification to use required cells/reagents for screening (max 120 words)** |
|       |

END